- Details
- Edward Christopher Dee discusses racial disparities in prostate cancer treatment and outcomes in the UK and US, highlighting findings from his team's Nature Reviews Urology publication. Drawing from multiple studies, including analysis of the National Cancer Database and VA health systems, he demonstrates how Black and Asian patients face higher rates of treatment refusal and delays compared to wh...
|
- Details
- Muhieddine Labban and Quoc-Dien Trinh discuss transportation barriers in prostate cancer care in Massachusetts. Their work reveals significant transportation disparities affecting Black patients, who are three to four times more likely to use public transportation for healthcare visits and spend substantially more time commuting. Despite Massachusetts having the fifth-largest transportation system...
|
- Details
- Sam Chang interviews Jason Brown about research on disparities in bladder cancer mortality between urban and rural settings from 2000 to 2020. Dr. Brown presents findings showing a significant decline in bladder cancer mortality in urban areas, particularly large metropolitan centers, while rates remain unchanged in rural areas. The study uses CDC data and Joinpoint Regression analysis to identify...
|
- Details
- Ruchika Talwar hosts Logan Galansky to discuss the transition from race-based to race-conscious medicine in clinical algorithms. Dr. Galansky discusses the importance of integrating race as a contextual factor rather than a biological proxy to improve health equity. She highlights the AHRQ report, which identifies algorithms that reduce healthcare disparities, including two related to prostate can...
|
- Details
- Isla Garraway discusses her team's study that explores how neighborhood deprivation, race, and ethnicity impact prostate cancer outcomes across California healthcare systems. Dr. Garraway highlights the significant disparities in prostate cancer incidence and outcomes, particularly among Black men and those in deprived neighborhoods. The study compares outcomes between veterans treated in the VA s...
|
- Details
- Ashish Kamat welcomes Siamak (Sia) Daneshmand to discuss the nuances of blue light cystoscopy and its effectiveness across different racial groups. Dr. Daneshmand discusses his team’s research into racial differences in tumor detection rates using blue light cystoscopy. He highlights the study's analysis of detection sensitivity across different races, revealing that while blue light enhances tumo...
|
- Details
- Ruchika Talwar is joined by Ashley Appleton and Efe Chantal Ghanney-Simons, discussed the future racial and ethnic composition of the urology workforce. The discussion, based on their study "The Future State of Race Ethnicity in Urology: A Workforce Projection From 2021-2061," highlighted the slow growth of underrepresented minorities in urology compared to their increasing proportion in the gener...
|
- Details
- Sam Chang is joined by James (Jed) Ferguson to explore disparities in the treatment of muscle-invasive bladder cancer. Dr. Ferguson's team delved into the National Cancer Database, revealing that a significant percentage of patients do not receive aggressive treatments post-TURBT, with factors such as age, comorbidity, race, insurance status, and treatment facility type playing crucial roles in th...
|
- Details
- Samuel Washington engages with Leanne Woods-Burnham to delve into prostate cancer screening for Black men in the U.S., highlighting their discussion at the SUO conference. Dr. Woods-Burnham emphasizes the decline in localized prostate cancer detection following 2012 guideline changes and a concerning rise in metastatic diagnoses, disproportionately affecting Black men. Despite recommendations for...
|
- Details
- Judd Moul discusses a study focusing on the mortality risk associated with androgen deprivation therapy (ADT) in Black versus white patients with prostate cancer. The study, a comprehensive analysis of a large cohort, indicates that African-American ethnicity may be protective for survival in both castrate-resistant and castrate-sensitive prostate cancer. This contradicts earlier perceptions, espe...
|
